Antigen-Specific Immunotherapeutic Vaccine for Experimental Autoimmune Myasthenia Gravis

Experimental autoimmune myasthenia gravis.

Injection of animals with purified acetylcholine receptor in complete Freund's adjuvant causes development of antibodies which crossreact with receptors in muscle. The crossreacting antibodies impair neuromuscular transmission. Animals with experimental autoimmune myasthenia gravis (EAMG) are excellent models for studying the complex mechanisms by which the autoimmune response to receptor in my...

Antigen-Specific Immunotherapeutic Vaccine

Erythropoietin Ameliorates Experimental Autoimmune Myasthenia Gravis

Myasthenia gravis (MG) is an autoimmune disorder characterized by weakness and fatigability of skeletal muscles. Erythropoietin (EPO) is a cytokine required to maintain erythroid cells. Recombinant human EPO (rHuEPO) was found to act also on immune cells. Beneficial effects of rHuEPO therapy have been demonstrated in several experimental autoimmune models. We have tested the effect of rHuEPO on...

Pathological Mechanisms in Experimental Autoimmune Myasthenia Gravis

Immunization of mammals with purified acetylcholine receptor protein (AChR) 1 results in an autoimmune response to skeletal muscle AChR which impairs neuromuscular transmission, causing experimental autoimmune myasthenia gravis (EAMG). In the introduction to the accompanying article (1) the striking similarities between EAMG and the human disease myasthenia gravis (MG) were reviewed. In that ar...

O 29: Autoimmune Myasthenia Gravis Introduction, Immunopathogenesis and Classification

Autoimmune Myasthenia Gravis (MG) is a unique disease among all autoimmune disorders in two ways. First, there are a wide range of sub-specialties involved in the diagnosis and management of MG; secondly MG is an autoimmune disorder whose autoimmunity is well established. In this paper I will cover these topics: history and epidemiology of MG followed by a brief overview on physiology of neurom...